弗卢可纳抗性 Vulvovaginal Candidosis:关于当前管理的最新情况
Karolina Akinosoglou1,2, Achilleas Livieratos3, Konstantinos Asimos4
1Department of Medicine, University of Patras, 265 04 Rio, Greece.
Pharmaceutics
|January 8, 2025
概括
管理流可纳耐药性阴腺候群 (FRVVC) 需要探索替代抗真菌药物和个性化治疗. 避免不必要的抗真菌使用和谨慎的抗生素处方对于有效的VVC管理至关重要.
科学领域:
- 菌类学 菌类学是指菌类学.
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 耐药性 *Candida* 种类 (*Candida albicans*, *Candida glabrata*, *Candida krusei*) 的流行率不断上升,这给管理带来了挑战.
- 需要使用替代治疗策略的富可纳耐药性阴腺候群病 (FRVVC).
- 过度使用抗真菌药物治疗非*Candida*感染有助于耐药性和治疗失败.
研究的目的:
- 审查目前对可纳耐药性 vulvovaginal candidiasis (FRVVC) 的管理策略.
- 探索替代抗真菌疗法和治疗方案.
- 强调使用抗生素对微生物群和抗真菌耐药性的影响.
主要方法:
- 对FRVVC管理研究的文献综述.
- 识别替代性抗真菌剂 (例如,玻利酸,尼斯塔丁,奥特塞可纳,IBREXAFUNGERP).
- 对治疗方案的分析,包括个性化退化 (ReCiDiF) 方法.
主要成果:
- 替代疗法对FRVVC有希望.
- 由于区域性耐药性变化,定制的治疗方案是必不可少的.
- ReCiDiF疗法提供了一个个性化的方法,以尽量减少剂量和控制感染.
- 抗生素的使用可能会破坏微生物群,增加VVC风险并促进可纳耐药性.
结论:
- 有效的FRVVC管理需要从高剂量维持转向个性化,退化治疗.
- 合理使用抗真菌药物和抗生素对于对抗耐药性和保护微生物群至关重要.
- 对新型药物和治疗策略的进一步研究是有必要的.
更多相关视频
相关概念视频
Surface Membrane Barriers
1.0K
The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
1.0K
Cystic Fibrosis: Management
139
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
139


